Kyowa Hakko Kirin says commercial production of biopharmaceuticals will begin rolling out of its new plant in 2017.
The HA5 plant at the Japanese drug company’s Takasaki facility will commence operations in 2016 with commercial amounts of injectable drugs available the year after.
Spokesman for Kyowa Hiroki Nakamura told in-Pharmatechnologist.com that the company plans to manufacture its own products “for European, US, and Japanese” markets and will comply with Good Manufacturing Practices (GMP) for all three regulatory bodies.
The company said that the new plant was commissioned in order to strengthen stability of the supply chain.
The plant – which will see an investment of approximately Y4.6bn ($48.9m) – will be four stories tall with a total floor space of approx. 4106 m2 and will produce some of the injectables being made at Kyowa’s Fuji plant as well as those being produced at the current Takasaki plant.